semaj83/ctmatch_classification huggingface dataset:
Patient description: A 51-year-old woman is seen in clinic for advice on osteoporosis. She has a past medical history of significant hypertension and diet-controlled diabetes mellitus. She currently smokes 1 pack of cigarettes per day. She was documented by previous LH and FSH levels to be in menopause within the last year. She is concerned about breaking her hip as she gets older and is seeking advice on osteoporosis prevention.

Clinical trial eligibility criteria: eligible ages (years): 20.0-75.0,  Healthy Men and non-pregnant women who are at least 20 years and under 75 years of age; and Female subjects cannot be pregnant or breast feeding Patients who are, in the opinion of the Investigator, able to comply with the requirements of the study; and Patients who have been adequately informed of the nature and risks of the study and who have given written informed consent prior to receiving study medication  Women who are pregnant, as determined by a urine pregnancy test, or breast-feeding Presence or history of congestive heart failure (NYHA class III/IV) within the prior 12 weeks Recent myocardial infarction (within the prior 12 weeks) Unstable angina pectoris Known or suspected renal insufficiency defined as creatinine>1.5mg/dl Known or suspected hepatic insufficiency defined as abnormal liver function tests (GOT/GPT) >3x upper normal limit (i.e., 120 U/l) Known hypomotility syndrome: (such as hypothyroidism or scleroderma) Recent major trauma within the prior 12 weeks Recent surgery requiring anesthesia including coronary artery bypass graft (within 12 weeks) Recent hospitalization (within 12 weeks)
Patient description: A 51-year-old woman is seen in clinic for advice on osteoporosis. She has a past medical history of significant hypertension and diet-controlled diabetes mellitus. She currently smokes 1 pack of cigarettes per day. She was documented by previous LH and FSH levels to be in menopause within the last year. She is concerned about breaking her hip as she gets older and is seeking advice on osteoporosis prevention.

Clinical trial eligibility criteria: eligible ages (years): 40.0-90.0,  Osteoporosis Adults between the ages of 40 to 90 Adults who been fractures prior to assessment Adults who have ability, well conscious to complete the questionnaires  Adults who have treatment currently will not in this study
Patient description: A 51-year-old woman is seen in clinic for advice on osteoporosis. She has a past medical history of significant hypertension and diet-controlled diabetes mellitus. She currently smokes 1 pack of cigarettes per day. She was documented by previous LH and FSH levels to be in menopause within the last year. She is concerned about breaking her hip as she gets older and is seeking advice on osteoporosis prevention.

Clinical trial eligibility criteria: eligible ages (years): 20.0-90.0,  Osteoporosis Postmenopausal women and men referred for bone density examination  Patients unable to sign consent for participation
Patient description: A 51-year-old woman is seen in clinic for advice on osteoporosis. She has a past medical history of significant hypertension and diet-controlled diabetes mellitus. She currently smokes 1 pack of cigarettes per day. She was documented by previous LH and FSH levels to be in menopause within the last year. She is concerned about breaking her hip as she gets older and is seeking advice on osteoporosis prevention.

Clinical trial eligibility criteria: eligible ages (years): 50.0-89.0,  Osteoporosis Female sex Age 50 to 89 years  Those who have opted out of being contacted for research on their general Park Nicollet clinic consent will not be recruited by mail Inability to sign consent form due to cognitive impairment. Those with dementia (ICD-9 diagnosis codes 331.0, 294.1, 294.10, 294.11, or 294.8) will excluded from mailed recruitment Measurement of hip BMD is not feasible (for example, those who have had bilateral hip replacement surgeries or who cannot have central DXA because of their body weight) Open leg or arm wounds at sites where ultrasound measurements are supposed to be taken, precluding such measurements
Patient description: A 51-year-old woman is seen in clinic for advice on osteoporosis. She has a past medical history of significant hypertension and diet-controlled diabetes mellitus. She currently smokes 1 pack of cigarettes per day. She was documented by previous LH and FSH levels to be in menopause within the last year. She is concerned about breaking her hip as she gets older and is seeking advice on osteoporosis prevention.

Clinical trial eligibility criteria: eligible ages (years): 50.0-79.0,  Osteoporosis Osteoporosis suspicion Age: 50 years (n = 500) and 60-79 years (n = 500) Post-menopausal status At least one of the clinical risk factors for fracture Low body mass index (< 19kg/m2) Previous fragility fracture Parental history of hip fracture Glucocorticoid treatment (≥ 5mg prednisolone daily or equivalent for 3 months or more) Current smoking  Treatment: osteoporosis medication Obesity: body mass index BMI > 30kg/m2 a refusal to participate in the study Healthy Age: 50 years (n = 50) and 60-79 years (n = 50) Post-menopausal status No diseases or treatments which may affect to bone health Treatment: osteoporosis medication a refusal to participate in the study
Patient description: A 51-year-old woman is seen in clinic for advice on osteoporosis. She has a past medical history of significant hypertension and diet-controlled diabetes mellitus. She currently smokes 1 pack of cigarettes per day. She was documented by previous LH and FSH levels to be in menopause within the last year. She is concerned about breaking her hip as she gets older and is seeking advice on osteoporosis prevention.

Clinical trial eligibility criteria: eligible ages (years): 50.0-80.0,  Osteoporosis Women between 50 and 80 years Hospitalized In health services, orthopedics, gynecology, surgery Able to respond to an easy questionnaire Able to give their agreement to participate in the study  Patients with dementia Patients can not express Patients at end of life Patients previously treated for osteoporosis or recent densitometry (BMD) <3 years Patients could not be seen in time by the nurse during their hospitalization Patients receiving a measure of legal protection
Patient description: A 51-year-old woman is seen in clinic for advice on osteoporosis. She has a past medical history of significant hypertension and diet-controlled diabetes mellitus. She currently smokes 1 pack of cigarettes per day. She was documented by previous LH and FSH levels to be in menopause within the last year. She is concerned about breaking her hip as she gets older and is seeking advice on osteoporosis prevention.

Clinical trial eligibility criteria: eligible ages (years): 35.0-70.0,  Hypertension Diabetes Smoking Cardiovascular Diseases All individuals between the ages of 35 and 70 and residing in the area allotted to the CHW will be offered screening Of the screened individuals, those with at least 1 cardiovascular risk factor (either one of Hypertension (BP>140/90), Diabetes (FBG >126) or current daily smoker (self-reported) will be enrolled in the study  Individuals who are bed-bound because of acute illness, or have a chronic condition that makes them bed-bound Individuals who refuse consent Individuals who do not reside in the community and are only visiting, therefore being unlikely to be available for continuous follow up. Individuals who have stayed less than 6 months in the study area, or whose name is not on the voter list of the area will be excluded Individuals who are not able to participate in the intervention due to significant disabilities, such as blindness, deafness or the intellectually disabled
Patient description: A 51-year-old woman is seen in clinic for advice on osteoporosis. She has a past medical history of significant hypertension and diet-controlled diabetes mellitus. She currently smokes 1 pack of cigarettes per day. She was documented by previous LH and FSH levels to be in menopause within the last year. She is concerned about breaking her hip as she gets older and is seeking advice on osteoporosis prevention.

Clinical trial eligibility criteria: eligible ages (years): 20.0-45.0,  Polycystic Ovary Syndrome PCOS diagnosis to three of the Rotterdam  pregnancy lactation taking vitamin d or calcium supplement in excess of a regular multivitamins diabetes mellitus uncontrolled hypertension liver disease renal disease secondary causes of hyperandrogenism metabolic bone disease thyroid dysfunction taking oral contraceptives taking hypoglycemic agents (metformin or thiazolidinediones) medication to affect plasma sex steroids for >/3 months before the study smokers
Patient description: A 51-year-old woman is seen in clinic for advice on osteoporosis. She has a past medical history of significant hypertension and diet-controlled diabetes mellitus. She currently smokes 1 pack of cigarettes per day. She was documented by previous LH and FSH levels to be in menopause within the last year. She is concerned about breaking her hip as she gets older and is seeking advice on osteoporosis prevention.

Clinical trial eligibility criteria: eligible ages (years): 45.0-70.0,  Osteoporosis Osteopenia Periodontal Disease Women between 45-70 years with Absorptiometry Dual Energy X-ray (DEXA) Control group: post-menopausal women with periodontal disease and normal osseous condition Study group: post-menopausal womens with periodontal disease and osteoporosis/osteopenia with and without bisphosphonate treatment (risedronate or ibandronate 150 mg) for longer than 3 months before the study and another  Patients with history of aggressive periodontitis and had received any periodontal treatment when they entered the study Patients with any systemic illness (except osteopenia/osteoporosis) Patients who received antibiotic or non-steroidal anti-inflammatory therapy in the 6 months prior to the study
Patient description: A 51-year-old woman is seen in clinic for advice on osteoporosis. She has a past medical history of significant hypertension and diet-controlled diabetes mellitus. She currently smokes 1 pack of cigarettes per day. She was documented by previous LH and FSH levels to be in menopause within the last year. She is concerned about breaking her hip as she gets older and is seeking advice on osteoporosis prevention.

Clinical trial eligibility criteria: eligible ages (years): 35.0-60.0,  Generalized Chronic Periodontitis Osteoporosis Male and Female Patients aged between 35.00 Year(s) to 60.00 Year(s) diagnosed with Osteoporosis and Chronic Periodontitis who are willing to participate in the study  Patients who are Systemically compromised and under medications such as steroids Patients who smoke.Pregnant and lactating mothers are excluded from the study
Patient description: A 51-year-old woman is seen in clinic for advice on osteoporosis. She has a past medical history of significant hypertension and diet-controlled diabetes mellitus. She currently smokes 1 pack of cigarettes per day. She was documented by previous LH and FSH levels to be in menopause within the last year. She is concerned about breaking her hip as she gets older and is seeking advice on osteoporosis prevention.

Clinical trial eligibility criteria: eligible ages (years): 40.0-95.0,  Post Menopausal Osteoporosis post menopausal osteoporosis women in whom a decision has been made to treat with Prolia in the last 4 weeks received their first prescription of Prolia in the last 4 weeks patient has provided informed consent before enrolling in the study  patients participating in ongoing or previous Denosumab clinical trials
Patient description: A 51-year-old woman is seen in clinic for advice on osteoporosis. She has a past medical history of significant hypertension and diet-controlled diabetes mellitus. She currently smokes 1 pack of cigarettes per day. She was documented by previous LH and FSH levels to be in menopause within the last year. She is concerned about breaking her hip as she gets older and is seeking advice on osteoporosis prevention.

Clinical trial eligibility criteria: eligible ages (years): 50.0-999.0,  Post Menopausal Osteoporosis Postmenopausal women Age 50 years or greater  Previously diagnosed osteoporosis, or receiving treatment for osteoporosis
Patient description: A 51-year-old woman is seen in clinic for advice on osteoporosis. She has a past medical history of significant hypertension and diet-controlled diabetes mellitus. She currently smokes 1 pack of cigarettes per day. She was documented by previous LH and FSH levels to be in menopause within the last year. She is concerned about breaking her hip as she gets older and is seeking advice on osteoporosis prevention.

Clinical trial eligibility criteria: eligible ages (years): 35.0-999.0,  Osteoporosis, Postmenopausal Osteoporosis, Steroid Induced Female patients with postmenopausal osteoporosis (T-score ≤-2,5 SD at any skeletal site) under osteoporosis treatment (except teriparatide) for at least one year with a history of ≥ low-energy fracture during the last 10 years prior the study Male patients ≥ 50 years old with idiopathic osteoporosis (T-score ≤-2,5 SD at any skeletal site) under osteoporosis treatment (except teriparatide) for at least one year with a history of ≥ low-energy fracture during the last 10 years prior the study Male and female patients with steroid-induced osteoporosis (T-score ≤-2,5 SD at any skeletal site) under osteoporosis treatment (except teriparatide) for at least one year with a history of ≥ low-energy fracture during the last 10 years prior the study  Prior use of teriparatide or PTH(1-84) Hypersensitivity to teriparatide regimen Pregnancy and lactation Hypercalcamia Renal deficiency (eGFR < 30 ml/min) Other bone metabolic diseases (including hyperparathyroidism and Paget's disease) except primary osteoporosis or steroid induced osteoporosis  Uninterpretable increases of alkaline phosphatase (ALP) Prior skeletal radiotherapy Skeletal malignancies or bone metastases
Patient description: A 51-year-old woman is seen in clinic for advice on osteoporosis. She has a past medical history of significant hypertension and diet-controlled diabetes mellitus. She currently smokes 1 pack of cigarettes per day. She was documented by previous LH and FSH levels to be in menopause within the last year. She is concerned about breaking her hip as she gets older and is seeking advice on osteoporosis prevention.

Clinical trial eligibility criteria: eligible ages (years): 50.0-999.0,  Hypovitaminosis D Spinal Disease Osteoporosis (Part 1, Retrospective Study) 50 years old or older Patients with any form of spinal fusion surgery performed by Dr. Daniel Fassett, MD, MBA, Neurosurgeon at OSF-INI from November 1, 2012 to October 31, 2014  Subjects diagnosed with chronic renal disease Stage IV or V, metastatic spinal disease, bariatric surgery, malabsorption syndrome, seizure medication and chronic steroid use greater than 3 months at time of surgery (Part 2, Observational Study) (Screening period July 1, 2015-June 30, 2016) 50 years old or older Serum Vitamin D level checked prior to or at surgery BMD exam performed anytime within 2 years prior to surgery Patients with any form of spinal fusion cervical, thoracic, lumbar, surgery performed by Dr. Daniel Fassett, MD, MBA, Neurosurgeon at OSF-INI from July 1, 2015 to May 31, 2016 Subjects diagnosed with Chronic Renal Disease with a GFR < 45 at Stage IV Metastatic Spinal Disease
Patient description: A 51-year-old woman is seen in clinic for advice on osteoporosis. She has a past medical history of significant hypertension and diet-controlled diabetes mellitus. She currently smokes 1 pack of cigarettes per day. She was documented by previous LH and FSH levels to be in menopause within the last year. She is concerned about breaking her hip as she gets older and is seeking advice on osteoporosis prevention.

Clinical trial eligibility criteria: eligible ages (years): 50.0-75.0,  Type 2 Diabetes Mellitus Bone Fractures presence of type 2 diabetes for at least 3 years (history of treatment for type 2 diabetes)  immobility coexisting metabolic bone disease or comorbidities affecting bone health previous treatment with osteoporosis medication or intake of medications known to affect bone metabolism (e.g. steroids) within 6 months prior to enrolment thiazolidinedione use
Patient description: A 51-year-old woman is seen in clinic for advice on osteoporosis. She has a past medical history of significant hypertension and diet-controlled diabetes mellitus. She currently smokes 1 pack of cigarettes per day. She was documented by previous LH and FSH levels to be in menopause within the last year. She is concerned about breaking her hip as she gets older and is seeking advice on osteoporosis prevention.

Clinical trial eligibility criteria: eligible ages (years): 20.0-90.0,  Osteoporosis age of at least 20 years, able to read and fill out the questionnaire, and willingness to participate  severe liver, heart, or kidney impairment, and tumor. Procedures of the study were in accordance with the Declaration of Helsinki and were approved by the local ethics committee
Patient description: A 58-year-old nonsmoker white female with mild exertional dyspnea and occasional cough is found to have a left lung mass on chest x-ray. She is otherwise asymptomatic. A neurologic examination is unremarkable, but a CT scan of the head shows a solitary mass in the right frontal lobe.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Cerebellar Disease Dementia Healthy Parkinson's Disease Right handed normal volunteers (18-65 years old) Patients with Parkinson's disease off medication Patients with cerebellar deficits Patients with frontal lobe lesions Patients with frontal lobe dementia  Subjects with personal or family history of seizures or other neurological disorders Pregnant women Volunteers or patients with severe coronary artery disease Metal in the cranium except mouth Intracardiac lines Increased intracranial pressure as evaluated by clinical means Cardiac pacemakers Intake of neuroleptics
Patient description: A 58-year-old nonsmoker white female with mild exertional dyspnea and occasional cough is found to have a left lung mass on chest x-ray. She is otherwise asymptomatic. A neurologic examination is unremarkable, but a CT scan of the head shows a solitary mass in the right frontal lobe.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Dementia Characterized as having behavioral manifestations using a standardized neuropsychiatric scale and interview FLD patients' frontal cognitive sysfunctions characterized using a short neurobehavioral test battery Patients must be able to be tested and cooperative with the procedures required in this protocol No contraindications to the use of Sertraline No medical conditions that can reasonably be expected to subject the patient to unwarranted risk (e.g., cancer) or require frequent changes in medication. Well-controlled medical conditions such as hypertension and diabetes will not be excluded Patients must not be pregnant or nursing and must be using effective contraception, if still at child-bearing age No history of prior severe traumatic brain injury or other severe neurologic or psychiatric condition, such as psychosis, stroke, multiple sclerosis, or spinal cord injury Not using any psychotropic medication which cannot be stopped 4 weeks before the study
Patient description: A 58-year-old nonsmoker white female with mild exertional dyspnea and occasional cough is found to have a left lung mass on chest x-ray. She is otherwise asymptomatic. A neurologic examination is unremarkable, but a CT scan of the head shows a solitary mass in the right frontal lobe.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Lung Cancer Histologically confirmed stage IIIB with metastatic pleural effusion or metastatic stage IV non-small cell lung cancer Large cell Adenocarcinoma Squamous cell Bronchioalveolar carcinoma Undifferentiated No small cell or carcinoid histologies At least 1 bidimensionally measurable or evaluable indicator lesion Measurable or evaluable indicator lesion(s) must be completely outside the radiation portal or there must be proof of disease progression No current CNS metastases at study entry No meningeal carcinomatosis Age: 18 and over Performance status: Zubrod 0-2 Life expectancy: Greater than 12 weeks Hematopoietic: Neutrophil count at least 1,500/mm3 Platelet count at least 100,000/mm3 Hepatic: Bilirubin no greater than upper limit of normal (ULN) SGOT and/or SGPT no greater than 2.5 times ULN if alkaline phosphatase less than ULN, OR alkaline phosphatase no greater than 4 times ULN if SGOT and/or SGPT less than ULN Renal: Creatinine clearance at least 50 mL/min Other: No concurrent illness that would effect assessment of this study Not pregnant or nursing Effective contraception required of all fertile patients PRIOR Biologic therapy: Not specified Chemotherapy: No prior systemic chemotherapy No other concurrent chemotherapy Endocrine therapy: Not specified Radiotherapy: See Disease Characteristics Prior radiotherapy for non-small cell lung cancer allowed Radiotherapy for new brain metastases (other than leptomeningeal disease) is allowed during study, but chemotherapy is stopped during and for 2 weeks following radiotherapy Concurrent radiotherapy to other sites allowed if there is no objective for disease progression Surgery: Not specified Other: No other concurrent experimental drug
Patient description: A 58-year-old nonsmoker white female with mild exertional dyspnea and occasional cough is found to have a left lung mass on chest x-ray. She is otherwise asymptomatic. A neurologic examination is unremarkable, but a CT scan of the head shows a solitary mass in the right frontal lobe.

Clinical trial eligibility criteria: eligible ages (years): 3.0-16.0,  Brain and Central Nervous System Tumors Histologically proven primitive neuroectodermal tumors of the central nervous system No metastatic disease within or outside the central nervous system Must have survived 1 week following surgery Postoperative CT scan and myelogram required Age: 3 to 16 Performance status: Not specified Life expectancy: Not specified Hematopoietic: No concurrent hematological disorder Hepatic: Not specified Renal: Renal dysfunction allowed Other: No prior history of malignant disease PRIOR Biologic therapy: Not specified Chemotherapy: Not specified Endocrine therapy: Not specified Radiotherapy: Not specified Surgery: See Disease Characteristics
Patient description: A 58-year-old nonsmoker white female with mild exertional dyspnea and occasional cough is found to have a left lung mass on chest x-ray. She is otherwise asymptomatic. A neurologic examination is unremarkable, but a CT scan of the head shows a solitary mass in the right frontal lobe.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Carcinoma, Non-Small-Cell Lung Histologically confirmed locally advanced NSCLC (squamous, large cell undifferentiated or adenocarcinoma) Disease limited to the thorax, adjacent mediastinum and neurovascular structures, and supraclavicular or scalene lymph node area, as defined by the AJCC Staging System. This includes patients with Stage IIIA and IIIB disease Performance status of 0-2 by Southwest Oncology Group criteria Medically inoperable patients (Stage I or II) Locoregional recurrent tumor following surgery will be eligible provided they meet other criteria